insulin glargine · Lantus

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Diabetes mellitus requiring insulin (Lantus, sanofi-aventis Deutschland GmbH)
Product first approved 2000EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (134)
Type 1 Diabetes
NCT07282054 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2022-04-13 – 2025-01-24 · Type 1 Diabetes
What this study did
NCT07070752 · Geropharm
2023-04-14 – 2023-11-28 · Type 1 Diabetes Mellitis
What this study did
NCT03952130 · Eli Lilly and Company
2019-05-29 – 2022-01-10 · Type 1 Diabetes Mellitus
What this study did
NCT03874715 · Sanofi
2019-03-11 – 2020-07-08 · Type 1 Diabetes Mellitus
What this study did
NCT03214367 · Eli Lilly and Company
2017-07-17 – 2019-08-22 · Type 1 Diabetes Mellitus
What this study did
NCT01194882 · Sanofi
2010-11-16 – 2018-02-01 · Diabetes Mellitus, Type 1
What this study did
NCT02273180 · Sanofi
2014-10 – 2016-07 · Type 1 Diabetes Mellitus
What this study did
NCT02518945 · University at Buffalo
2015-08 – 2016-04 · Type 1 Diabetes Mellitus
What this study did
NCT02034513 · Novo Nordisk A/S
2014-01-05 – 2016-01-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01223131 · Sanofi
2011-02 – 2014-03 · Type 1 Diabetes Mellitus
What this study did
NCT01192711 · Consorzio Mario Negri Sud
2009-05 – 2011-10 · Type 1 Diabetes
What this study did
NCT00993473 · Sanofi
2009-10 – 2011-03 · Type 1 Diabetes Mellitus
What this study did
NCT00694122 · Massachusetts General Hospital
2005-06 – 2010-11 · Type 1 Diabetes, Dawn Phenomenon
What this study did
NCT00127634 · Eli Lilly and Company
2005-07 – 2008-05 · Diabetes Mellitus, Type 1
What this study did
NCT00356109 · Eli Lilly and Company
2006-08 – 2008-05 · Diabetes Mellitus, Type 1
What this study did
NCT00115570 · Sanofi
2005-04 – 2006-11 · Diabetes Mellitus, Insulin-Dependent
What this study did
NCT00095082 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00272090 · Sanofi
2002-11 – 2005-12 · Diabetes Mellitus, Type 1
What this study did
NCT00046501 · Sanofi
2002-11 – 2005-02 · Diabetes Mellitus
What this study did
NCT00004984 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1994-02 – 2003-06 · Diabetes Mellitus, Type 1
What this study did
NCT00312104 · Novo Nordisk A/S
2002-04 – 2003-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06619301 · Loyola University
2024-04-01 – 2027-01-01 · Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
What this study did
NCT06881264 · Jiangsu HengRui Medicine Co., Ltd.
2024-04-30 – 2025-09-19 · Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
What this study did
NCT04974528 · Mannkind Corporation
2021-09-29 – 2025-04-29 · Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT06107153 · University of Basrah
2023-11-01 – 2024-11-01 · Type2diabetes
What this study did
NCT05662332 · Eli Lilly and Company
2023-01-14 – 2024-07-19 · Type 2 Diabetes, T2D
What this study did
NCT05545800 · Xiangya Hospital of Central South University
2022-09-01 – 2024-06-01 · Type 2 Diabetes Mellitus
What this study did
NCT05462756 · Eli Lilly and Company
2022-08-11 – 2024-02-27 · Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
What this study did
NCT05413369 · Sanofi
2022-07-07 – 2023-10-20 · Type 2 Diabetes Mellitus
What this study did
NCT04460326 · Boston Medical Center
2020-12-07 – 2023-05-27 · Type 2 Diabetes Treated With Insulin
What this study did
NCT04605991 · Eli Lilly and Company
2020-11-04 – 2022-02-04 · Type 2 Diabetes
What this study did
NCT02194595 · Mount Sinai Hospital, Canada
2014-09 – 2022-02 · Type 2 Diabetes
What this study did
NCT01794143 · GRADE Study Group
2013-05 – 2021-04-30 · Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
What this study did
NCT03689374 · Novo Nordisk A/S
2018-10-01 – 2021-02-22 · Diabetes Mellitus, Type 2
What this study did
NCT03952143 · Eli Lilly and Company
2019-05-27 – 2021-01-20 · Type 2 Diabetes Mellitus
What this study did
NCT03130426 · Population Health Research Institute
2017-06-27 – 2020-09-30 · Type 2 Diabetes Mellitus
What this study did
NCT02192424 · Mount Sinai Hospital, Canada
2014-07 – 2020-09 · Type 2 Diabetes
What this study did
NCT02623998 · Population Health Research Institute
2016-07-09 – 2019-11-30 · Type 2 Diabetes Mellitus
What this study did
NCT03529123 · Sanofi
2018-06-19 – 2019-11-25 · Type 2 Diabetes Mellitus
What this study did
NCT01779362 · RISE Study Group
2013-04 – 2019-08 · Prediabetes, Type 2 Diabetes
What this study did
NCT02752113 · Institut für Pharmakologie und Präventive Medizin
2016-04 – 2019-05 · Diabetes Mellitus Type 2
What this study did
NCT03214380 · Eli Lilly and Company
2017-07-14 – 2019-03-13 · Type 2 Diabetes Mellitus
What this study did
Phase 2/3 (1)
Type 1 Diabetes
NCT00447213 · Eli Lilly and Company
2007-04 – 2008-05 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (20)
Type 1 Diabetes
NCT01194245 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type 1
What this study did
NCT01049412 · Eli Lilly and Company
2010-01 – 2011-01 · Diabetes Mellitus, Type 1
What this study did
NCT00883558 · Halozyme Therapeutics
2009-05 – 2010-04 · Diabetes Mellitus, Type 1
What this study did
NCT00612040 · Novo Nordisk A/S
2008-01 – 2008-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT04542148 · University of Alabama at Birmingham
2022-02-10 – 2026-12-31 · Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
What this study did
NCT03922750 · Novo Nordisk A/S
2019-05-09 – 2020-01-27 · Diabetes Mellitus, Type 2
What this study did
NCT03751657 · Novo Nordisk A/S
2018-11-29 – 2020-01-17 · Diabetes Mellitus, Type 2
What this study did
NCT03951805 · Novo Nordisk A/S
2019-05-09 – 2020-01-17 · Diabetes Mellitus, Type 2
What this study did
NCT02470039 · Novo Nordisk A/S
2015-06-01 – 2015-12-31 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01399645 · Centre hospitalier de l'Université de Montréal (CHUM)
2011-05 – 2014-06 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
What this study did
NCT01011868 · Boehringer Ingelheim
2009-11 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT01194258 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type II
What this study did
NCT00850096 · CPEX Pharmaceuticals Inc.
2009-01 – 2010-03 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07461103 · Alexandria University
2024-06-22 – 2025-08-10 · Pemphigus Vulgaris, Skin Erosion, Autoimmune Blistering Disease
What this study did
NCT06007508 · HealthPartners Institute
2022-05-31 – 2023-02-28 · DKA
What this study did
NCT01910194 · Profil Institut für Stoffwechselforschung GmbH
2013-12 – 2014-10 · Diabetes Mellitus
What this study did
NCT00764556 · St George's, University of London
2008-05 – 2009-05 · COPD, Hyperglycemia
What this study did
NCT01000922 · Biodel
2006-06 – 2008-01 · Diabetes Mellitus
What this study did
Phase 1/2 (1)
Type 1 Diabetes
NCT01053728 · Sanofi
2010-02 – 2010-11 · Type 1 Diabetes Mellitus
What this study did
Phase 1 (47)
Type 1 Diabetes
NCT04236895 · Gan and Lee Pharmaceuticals, USA
2018-07-10 – 2018-11-28 · Diabetes Mellitus, Type 1
What this study did
NCT02506647 · Gan and Lee Pharmaceuticals, USA
2015-12 – 2016-09 · Diabetes Mellitus, Type 1
What this study did
NCT02059174 · Merck Sharp & Dohme LLC
2014-02-10 – 2015-04-27 · Type 1 Diabetes Mellitus
What this study did
NCT02220296 · Novo Nordisk A/S
2014-08-20 – 2015-03-31 · Healthy, Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01838083 · Sanofi
2013-04 – 2013-08 · Type1 Diabetes
What this study did
NCT01704417 · Novo Nordisk A/S
2012-10 – 2013-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01357603 · Wockhardt
2011-06 – 2012-08 · Type1 Diabetes
What this study did
NCT01493115 · Sanofi
2011-11 – 2012-04 · Type 1 Diabetes Mellitus
What this study did
NCT01349855 · Sanofi
2011-03 – 2011-05 · Type 1 Diabetes Mellitus
What this study did
NCT01146678 · Sanofi
2010-06 – 2011-01 · Type 1 Diabetes Mellitus
What this study did
NCT01195454 · Sanofi
2010-08 – 2010-12 · Type 1 Diabetes Mellitus
What this study did
NCT00961324 · Novo Nordisk A/S
2009-07-27 – 2009-10-26 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01868529 · Novo Nordisk A/S
2008-01 – 2008-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01497574 · Novo Nordisk A/S
2005-05 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT03945656 · Novo Nordisk A/S
2019-05-07 – 2021-09-27 · Diabetes Mellitus, Type 2
What this study did
NCT02803918 · Sanofi
2017-05-17 – 2020-01-27 · Type 2 Diabetes Mellitus
What this study did
NCT03170544 · Merck Sharp & Dohme LLC
2017-08-16 – 2018-11-08 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
What this study did
NCT02713477 · Sanofi
2016-04 – 2016-06 · Type 2 Diabetes Mellitus
What this study did
NCT02479022 · Novo Nordisk A/S
2015-06 – 2015-12 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT02012465 · Washington University School of Medicine
2013-09 – 2015-05 · Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
What this study did
NCT01809184 · Novo Nordisk A/S
2013-03-04 – 2013-09-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01796366 · Novo Nordisk A/S
2013-02-21 – 2013-08-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01597713 · Novo Nordisk A/S
2012-05 – 2012-10 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00574912 · Vanderbilt University Medical Center
2007-03 – 2010-01 · Type 2 Diabetes
What this study did
NCT00971659 · Profil Institut für Stoffwechselforschung GmbH
2008-01 – 2008-11 · Type 2 Diabetes
What this study did
NCT00511472 · Merck Sharp & Dohme LLC
2007-07 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
NCT00824668 · Novo Nordisk A/S
2007-08 – 2007-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00184613 · Novo Nordisk A/S
2005-05 – 2006-01 · Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
What this study did
Other / comorbidity
NCT02587741 · Third Affiliated Hospital, Sun Yat-Sen University
2015-07 – 2025-07 · Diabetic Retinopathy
What this study did
NCT07588906 · Jiangsu HengRui Medicine Co., Ltd.
2024-02-26 – 2024-07-23 · Healthy Subjects
What this study did
NCT03904199 · H. Lee Moffitt Cancer Center and Research Institute
2019-04-04 – 2021-11-02 · Hyperglycemia
What this study did
NCT01688635 · Eli Lilly and Company
2012-09 – 2013-02 · Healthy
What this study did
NCT01634165 · Eli Lilly and Company
2012-07 – 2012-09 · Healthy Volunteers
What this study did
NCT01476345 · Eli Lilly and Company
2011-11 – 2012-07 · Diabetes Mellitus
What this study did
NCT01152242 · Merck Sharp & Dohme LLC
2010-08 – 2012-05 · Diabetes
What this study did
NCT01153100 · University of Colorado, Denver
2010-04 – 2012-02 · Diabetes
What this study did
NCT01334034 · Novo Nordisk A/S
2011-04-11 – 2011-09-16 · Diabetes, Healthy
What this study did
NCT00652288 · Yale University
2007-04 – 2011-09 · Diabetes Mellitus, Type I
What this study did
NCT01002768 · Novo Nordisk A/S
2009-10 – 2010-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00348972 · Sanofi
started 2002-02 · Hyperglycemia, Diabetes Mellitus
What this study did
Phase 4 (207)
Type 1 Diabetes
NCT03463564 · University of Campania Luigi Vanvitelli
2016-01 – 2026-12 · Type 1 Diabetes Mellitus
What this study did
NCT07872475 · Marmara University
2025-05-01 – 2026-05-01 · Type 1 Diabetes Mellitus
What this study did
NCT05614089 · Jing Luo
2023-03-15 – 2025-03-19 · Diabetes Mellitus, Type 1, Type 1 Diabetes
What this study did
NCT06717191 · Life for a Child Program, Diabetes Australia
2022-06-09 – 2024-08-02 · Type 1 Diabetes
What this study did
NCT04623086 · University of Washington
2020-02-14 – 2023-12-31 · Type 1 Diabetes
What this study did
NCT06624943 · Life for a Child Program, Diabetes Australia
2022-03-14 – 2023-05-05 · Type 1 Diabetes (T1D)
What this study did
NCT05709938 · King Edward Medical University
2019-11-01 – 2021-04-20 · To Assess the Glycemic Control of Insulin Glargine in Combination With Regular Insulin in Type 1 Diabetes in Children
What this study did
NCT03107208 · University of Colorado, Denver
2017-07-21 – 2021-03-13 · Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
What this study did
NCT04664764 · Ain Shams University
2019-02-21 – 2021-03-10 · Type 1 Diabetes Mellitus With Hypoglycemia, type1diabetes
What this study did
NCT04157738 · Emory University
2019-11-27 – 2020-12-17 · Diabetes Mellitus, Type 1 Diabetes
What this study did
NCT03260868 · Sanofi
2017-09-19 – 2018-11-22 · Type 1 Diabetes Mellitus
What this study did
NCT03312478 · Sanofi
2017-10-13 – 2018-08-19 · Type 1 Diabetes
What this study did
NCT01204593 · Sanofi
2010-11 – 2013-01 · Diabetes Mellitus, Type 1
What this study did
NCT01440439 · Buckinghamshire Healthcare NHS Trust
2011-11 – 2012-06 · Diabetes Mellitus, Type 1
What this study did
NCT00964574 · Sanofi
2009-07 – 2010-07 · Diabetes Mellitus, Type 1
What this study did
NCT00505882 · University of Texas Southwestern Medical Center
2007-07 – 2008-12 · Type 1 Diabetes
What this study did
NCT00340613 · Baylor College of Medicine
2006-06 – 2007-06 · Type 1 Diabetes
What this study did
NCT00313742 · Novo Nordisk A/S
2006-04 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00206401 · Baylor College of Medicine
2004-11 – 2006-10 · Type 1 Diabetes
What this study did
NCT00360984 · Newcastle University
2003-05 – 2004-09 · Type 1 Diabetes Mellitus
What this study did
NCT00276393 · Mayo Clinic
2002-07 – 2003-12 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT07173712 · Yanbing Li
2026-03-15 – 2027-12-31 · Type 2 Diabetes
What this study did
NCT07307235 · Shanghai Zhongshan Hospital
2025-12-13 – 2027-12-30 · Type 2 Diabetes
What this study did
NCT06671587 · Sanofi
2024-12-10 – 2026-09-18 · Type 2 Diabetes (T2D)
What this study did
NCT06716424 · Sanofi
2025-01-06 – 2026-06-12 · Type 2 Diabetes
What this study did
NCT06370715 · Eli Lilly and Company
2024-04-18 – 2025-09-02 · Diabetes Mellitus, Type 2
What this study did
NCT05579119 · Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
2022-07-06 – 2023-08-24 · Type 2 Diabetes
What this study did
NCT05552859 · Sanofi
2022-12-05 – 2023-08-04 · Type 2 Diabetes Mellitus, Renal Impairment
What this study did
NCT05114590 · Sanofi
2022-01-27 – 2023-04-14 · Type 2 Diabetes Mellitus
What this study did
NCT04893148 · Chungbuk National University Hospital
2020-05-26 – 2022-12-30 · Type 2 Diabetes Mellitus, Glucose, High Blood
What this study did
NCT03660553 · University of Miami
2018-10-10 – 2022-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT04864977 · Eli Lilly and Company
2021-08-16 – 2022-06-06 · Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
What this study did
NCT04567225 · The Cleveland Clinic
2020-10-01 – 2021-08-27 · Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT04153981 · Eli Lilly and Company
2019-12-16 – 2021-07-30 · Type 2 Diabetes Mellitus
What this study did
NCT04196231 · University of Campania Luigi Vanvitelli
2019-11-27 – 2020-10-20 · Type 2 Diabetes
What this study did
NCT03670641 · Sandra Sobel
2019-03-26 – 2020-07-31 · Type 2 Diabetes Mellitus
What this study did
NCT03359837 · Sanofi
2018-01-20 – 2020-06-29 · Type 2 Diabetes Mellitus
What this study did
NCT03881995 · University Hospital Tuebingen
2019-03-18 – 2020-06-29 · Diabetes Mellitus, Type 2
What this study did
NCT02408120 · Emory University
2015-10 – 2019-12-11 · Diabetes Mellitus, Type 2
What this study did
NCT03631121 · Nanjing First Hospital, Nanjing Medical University
2018-08-15 – 2019-07-30 · Type2 Diabetes
What this study did
NCT02987751 · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
2016-12-29 – 2019-06 · Type2 Diabetes
What this study did
NCT03659383 · Nanjing First Hospital, Nanjing Medical University
2018-09-20 – 2019-03-31 · Type2 Diabetes
What this study did
NCT02561130 · Population Health Research Institute
2015-12 – 2018-12-31 · Type 2 Diabetes Mellitus
What this study did
NCT03349840 · Weill Cornell Medical College in Qatar
2018-01-07 – 2018-12-31 · Type2 Diabetes
What this study did
NCT01717911 · Taipei Veterans General Hospital, Taiwan
2010-09 – 2018-12 · Type 2 Diabetes
What this study did
NCT03112538 · Clinical Research Centre, Malaysia
2016-01 – 2018-12 · Type 2 Diabetes Mellitus
What this study did
NCT03350984 · Universidad de Guanajuato
2017-11-02 – 2018-07-01 · Type 2 Diabetes Mellitus
What this study did
NCT04739241 · Consorci Sanitari Integral
2014-01-24 – 2018-06-19 · Type 2 Diabetes Treated With Insulin
What this study did
NCT02836704 · Sanofi
2016-09-09 – 2018-04-26 · Diabetes Mellitus, Type 2
What this study did
NCT02545842 · Sanofi
2015-09-07 – 2018-04-20 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (62)
Type 1 Diabetes
NCT06487598 · Hirabai Cowasji Jehangir Medical Research Institute
2024-07-01 – 2025-07 · Type 1 Diabetes
What this study did
NCT04383990 · King Abdullah International Medical Research Center
2020-02-28 – 2020-11-30 · Type1diabetes, Fasting, Insulin
What this study did
NCT03557892 · Azienda Ospedaliero-Universitaria Careggi
2018-04-01 – 2020-01-02 · Diabetes Mellitus, Type 1
What this study did
NCT02548494 · Chattanooga-Hamilton County Hospital Authority
2015-11 – 2019-02-01 · Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
What this study did
NCT02824510 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2014-08 – 2017-01 · Type 1 Diabetes
What this study did
NCT02871180 · Diabeteszentrum Bad Lauterberg im Harz
2003-03 – 2016-08 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT02204839 · Northumbria University
2014-01 – 2015-01 · Type 1 Diabetes Mellitus
What this study did
NCT01424046 · University of Pittsburgh
2011-05 – 2014-11 · Type 1 Diabetes
What this study did
NCT00357890 · Nemours Children's Clinic
2005-12 – 2014-10 · Diabetes Mellitus, Insulin-Dependent
What this study did
NCT00564018 · University of Texas Southwestern Medical Center
2006-09 – 2011-04 · Type 1 Diabetes
What this study did
NCT00659165 · University of New Mexico
2008-04 – 2011-01 · Diabetes Mellitus
What this study did
NCT00417989 · Medtronic MiniMed, Inc.
2007-01 – 2010-06 · Type 1 Diabetes
What this study did
NCT00869414 · Johns Hopkins University
2009-07 – 2010-03 · Type 1 Diabetes, Hypoglycemia
What this study did
Type 2 Diabetes
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT04553380 · Shenzhen Second People's Hospital
2020-12-01 – 2022-03-31 · Type 2 Diabetes
What this study did
NCT04074603 · Jian-hua Ma
2019-09-01 – 2021-12-31 · Type 2 Diabetes
What this study did
NCT04484779 · Eli Lilly and Company
2020-07-14 – 2020-12-22 · Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT03829891 · Xijing Hospital
2018-08-07 – 2020-12-04 · Type 2 Diabetes Mellitus
What this study did
NCT03455985 · Ohio State University
2018-05-01 – 2020-09-11 · Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
What this study did
NCT03406663 · Seoul National University Hospital
2017-10-01 – 2020-07-14 · Type 2 Diabetes Mellitus
What this study did
NCT03180281 · First Affiliated Hospital Xi'an Jiaotong University
2017-07-01 – 2020-01-01 · Type 2 Diabetes Mellitus
What this study did
NCT03983187 · Majianhua
2019-06-15 – 2019-12-31 · Type 2 Diabetes
What this study did
NCT04093284 · Nanjing First Hospital, Nanjing Medical University
2019-09-12 – 2019-10-30 · Diabetes Mellitus, Type 2
What this study did
NCT02846233 · University of California, San Francisco
2016-08 – 2018-12 · Type 2 Diabetes Mellitus
What this study did
NCT02694289 · Maya Guglin
2016-11 – 2018-09-10 · Type 2 Diabetes Mellitus
What this study did
NCT01257087 · Imperial College London
2010-12 – 2016-08 · Type 2 Diabetes Mellitus, Obesity
What this study did
NCT02222623 · Inova Health Care Services
2015-04 – 2016-05 · Diabetes, Type 2
What this study did
NCT02026310 · Qifu Li
2014-01 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT02540486 · LMC Diabetes & Endocrinology Ltd.
2013-12 – 2015-03 · Type 2 Diabetes Mellitus
What this study did
NCT01089569 · HealthPartners Institute
2010-04 – 2013-05 · Type 2 Diabetes
What this study did
NCT01335763 · University of Alberta
2011-04 – 2012-10 · Type 2 Diabetes
What this study did
NCT00978263 · Chongqing Medical University
2009-02 – 2012-06 · Diabetes
What this study did
NCT00506194 · Taipei Veterans General Hospital, Taiwan
2005-10 – 2011-12 · Type 2 Diabetes
What this study did
NCT01334606 · Becton, Dickinson and Company
2011-03 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT01213563 · Imperial College London
2009-01 – 2010-09 · Diabetes Mellitus, Type 2
What this study did
NCT00948584 · Hallym University Medical Center
2007-11 – 2008-12 · Diabetes Mellitus, Type 2
What this study did
NCT00457093 · Diabetes Care Center
2006-10 – 2007-05 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07568574 · Enhanced Emirates Limited
2026-03-12 – 2033-03-01 · Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
What this study did
NCT07171684 · Rutgers, The State University of New Jersey
2025-11-26 – 2027-05-15 · Diabetes in Pregnancy, Gestational Diabetes
What this study did
NCT06419777 · Thomas Jefferson University
2024-09-01 – 2026-05 · Gestational Diabetes, Pregnancy Related
What this study did
NCT06419803 · Thomas Jefferson University
2024-09-01 – 2026-05 · Gestational Diabetes, Pregnancy Related
What this study did
NCT06178874 · Ain Shams University
2023-12-01 – 2024-06-01 · Glycemic Control, Insulin, Critical Illness
What this study did
NCT06056167 · King Faisal Specialist Hospital & Research Center
2023-05-17 – 2024-05-30 · Diabetes Mellitus, Critical Illness, Hyperglycemia
What this study did
NCT05219942 · Ain Shams University
2020-12-01 – 2022-07 · Chronic Kidney Diseases
What this study did
NCT02930044 · University of Maryland, Baltimore
2016-10 – 2021-11-01 · Diabetic Ketoacidosis
What this study did
NCT03001323 · Hennepin Healthcare Research Institute
2017-01 – 2020-09-25 · Diabetes Mellitus
What this study did
NCT01914146 · University of British Columbia
2015-04 – 2018-01-02 · Orthostatic Hypotension, Diabetes, Syncope
What this study did
Used as active comparator (158)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (73)
Type 1 Diabetes
NCT03740919 · Eli Lilly and Company
2019-04-07 – 2021-07-02 · Type 1 Diabetes Mellitus
What this study did
NCT03338023 · Eli Lilly and Company
2018-03-23 – 2020-03-05 · Type 1 Diabetes
What this study did
NCT04022993 · Geropharm
2018-07-04 – 2019-05-15 · Diabetes Mellitus, Type 1, Diabetes Mellitus
What this study did
NCT02666430 · Mylan Inc.
2015-12 – 2017-07 · Type 1 Diabetes Mellitus
What this study did
NCT02059161 · Merck Sharp & Dohme LLC
2013-10-17 – 2015-11-12 · Type 1 Diabetes Mellitus
What this study did
NCT01481779 · Eli Lilly and Company
2012-01 – 2014-06 · Diabetes Mellitus, Type 1
What this study did
NCT01421147 · Eli Lilly and Company
2011-08 – 2013-04 · Diabetes Mellitus, Type 1
What this study did
NCT01569841 · Novo Nordisk A/S
2012-04 – 2012-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01079234 · Novo Nordisk A/S
2010-03 – 2011-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00982228 · Novo Nordisk A/S
2009-09-01 – 2010-11-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT07920939 · Jiangsu HengRui Medicine Co., Ltd.
2026-11 – 2028-07 · Type 2 Diabetes
What this study did
NCT06767735 · Gan & Lee Pharmaceuticals.
2025-02-17 – 2026-08-17 · Diabetes
What this study did
NCT05098470 · University of Alabama at Birmingham
2022-03-07 – 2026-07-29 · Type 2 Diabetes
What this study did
NCT06767761 · Gan & Lee Pharmaceuticals.
2025-02-18 – 2026-04-09 · Diabetes
What this study did
NCT05803421 · Eli Lilly and Company
2023-04-03 – 2026-03-16 · Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
What this study did
NCT06871761 · Jiangsu HengRui Medicine Co., Ltd.
2024-05-08 – 2025-05-13 · Adult Patients With Type 2 Diabetes
What this study did
NCT05699408 · Jiangsu HengRui Medicine Co., Ltd.
2023-03-31 – 2024-11-23 · Type 2 Diabetes
What this study did
NCT05702073 · Jiangsu HengRui Medicine Co., Ltd.
2023-03-31 – 2024-06-11 · Type 2 Diabetes Mellitus
What this study did
NCT05767255 · Hospital Universitario San Ignacio
2022-12-01 – 2023-08-30 · Diabetes Mellitus, Type 2 Treated With Insulin
What this study did
NCT04093752 · Eli Lilly and Company
2019-12-09 – 2021-11-24 · Type 2 Diabetes
What this study did
NCT03730662 · Eli Lilly and Company
2018-11-20 – 2021-04-22 · Type 2 Diabetes Mellitus
What this study did
NCT03338010 · Eli Lilly and Company
2018-03-22 – 2020-03-18 · Type 2 Diabetes
What this study did
NCT03371108 · Gan and Lee Pharmaceuticals, USA
2017-10-31 – 2019-04-17 · Diabetes Mellitus, Type 2
What this study did
NCT02501161 · Novo Nordisk A/S
2016-01-31 – 2018-10-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01621178 · Eli Lilly and Company
2012-07 – 2016-12 · Type 2 Diabetes, Chronic Kidney Disease
What this study did
NCT01959529 · Novo Nordisk A/S
2013-10-29 – 2016-10-16 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02420262 · Novo Nordisk A/S
2015-07-26 – 2016-10-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02302716 · Eli Lilly and Company
2014-12 – 2016-07 · Diabetes Mellitus, Type 2
What this study did
NCT02106364 · Eli Lilly and Company
2015-02 – 2016-06 · Diabetes Mellitus, Type 2
What this study did
NCT02128932 · Novo Nordisk A/S
2014-08-04 – 2015-09-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01894568 · Eli Lilly and Company
2013-07 – 2015-04 · Type 2 Diabetes Mellitus
What this study did
NCT02059187 · Merck Sharp & Dohme LLC
2014-02-11 – 2015-03-11 · Type 2 Diabetes Mellitus
What this study did
NCT01648582 · Eli Lilly and Company
2012-07 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01952145 · Novo Nordisk A/S
2013-09-20 – 2014-11-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01435616 · Eli Lilly and Company
2011-11 – 2014-01 · Diabetes Mellitus, Type 2
What this study did
NCT01582451 · Eli Lilly and Company
2012-05 – 2013-12 · Diabetes Mellitus, Type 2
What this study did
NCT01468987 · Eli Lilly and Company
2011-12 – 2013-08 · Diabetes Mellitus, Type 2
What this study did
NCT01584232 · Eli Lilly and Company
2012-04 – 2013-07 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (7)
Type 2 Diabetes
NCT06688123 · Jiangsu HengRui Medicine Co., Ltd.
2025-01-08 – 2026-04-22 · Type 2 Diabetes
What this study did
NCT03352674 · Universitas Indonesia
2016-09 – 2018-12-01 · Diabetes Mellitus
What this study did
NCT01027871 · Eli Lilly and Company
2010-01 – 2011-01 · Diabetes Mellitus, Type 2
What this study did
NCT00611884 · Novo Nordisk A/S
2008-01 – 2008-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00614055 · Novo Nordisk A/S
2008-01 – 2008-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00147745 · Daiichi Sankyo
2005-06 – 2008-01 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT04591457 · Universitas Indonesia
2020-10 – 2021-08 · Diabetes Mellitus
What this study did
Phase 1 (34)
Type 1 Diabetes
NCT03400501 · Yale University
2017-10-01 – 2021-06-07 · Type 1 Diabetes Mellitus
What this study did
NCT03965013 · Novo Nordisk A/S
2019-06-05 – 2019-12-14 · Diabetes Mellitus, Type 1, Healthy Volunteers
What this study did
NCT02536859 · Novo Nordisk A/S
2015-08-31 – 2016-04-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01925989 · Eli Lilly and Company
2013-11 – 2015-10 · Type 1 Diabetes Mellitus
What this study did
NCT01771250 · Eli Lilly and Company
2013-10 – 2014-12 · Diabetes Mellitus, Type 1
What this study did
NCT01769404 · Eli Lilly and Company
2013-02 – 2013-12 · Diabetes Mellitus, Type 1
What this study did
NCT01784211 · Eli Lilly and Company
2013-02 – 2013-11 · Diabetes Mellitus, Type 1
What this study did
NCT01600950 · Eli Lilly and Company
2012-05 – 2012-07 · Diabetes Mellitus, Type 1
What this study did
NCT01114542 · Novo Nordisk A/S
2010-05-03 – 2010-08-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01030926 · Novo Nordisk A/S
2009-12 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00964418 · Novo Nordisk A/S
2009-08 – 2009-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT05596747 · Eli Lilly and Company
2022-11-30 – 2023-10-10 · Diabetes Mellitus, Type 2
What this study did
NCT04957914 · Eli Lilly and Company
2021-07-14 – 2022-10-17 · Type 2 Diabetes Mellitus
What this study did
NCT05248841 · Lannett Company, Inc.
2022-03-08 – 2022-08-31 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
What this study did
NCT04575181 · Novo Nordisk A/S
2020-10-21 – 2021-12-24 · Diabetes Mellitus, Type 2
What this study did
NCT04262661 · Novo Nordisk A/S
2020-03-02 – 2020-09-25 · Healthy Volunteers, Diabetes Mellitus, Type 2
What this study did
NCT04136067 · Novo Nordisk A/S
2019-10-29 – 2020-08-23 · Diabetes Mellitus, Type 2
What this study did
NCT03367377 · Eli Lilly and Company
2018-01-03 – 2018-10-03 · Diabetes Mellitus, Type 2
What this study did
NCT03095651 · Merck Sharp & Dohme LLC
2017-04-12 – 2018-01-30 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
What this study did
NCT02942914 · Eli Lilly and Company
2016-12-20 – 2017-10-18 · Diabetes Mellitus, Type 2
What this study did
NCT02197520 · Eli Lilly and Company
2014-07 – 2015-06 · Diabetes Mellitus, Type 2
What this study did
NCT01865292 · Novo Nordisk A/S
2006-08 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03555305 · Eli Lilly and Company
2018-09-26 – 2019-11-04 · Healthy
What this study did
NCT03025009 · Eli Lilly and Company
2017-03-06 – 2018-04-11 · Healthy
What this study did
NCT02152384 · Eli Lilly and Company
2014-06 – 2014-12 · Diabetes Mellitus, Type 1
What this study did
NCT01654380 · Eli Lilly and Company
2012-07 – 2013-10 · Healthy Volunteers, Diabetes Mellitus, Type 1
What this study did
NCT01374178 · Eli Lilly and Company
2011-06 – 2011-07 · Diabetes Mellitus
What this study did
NCT00810589 · Medical University of Graz
2008-11 – 2008-12 · Diabetes, Type I
What this study did
NCT01497535 · Novo Nordisk A/S
2004-05-27 – 2004-10-31 · Diabetes, Healthy
What this study did
Phase 4 (36)
Type 1 Diabetes
NCT03668808 · Sansum Diabetes Research Institute
2018-11-16 – 2020-09-19 · Diabetes Mellitus, Type 1
What this study did
NCT02192450 · Nordsjaellands Hospital
2015-01 – 2019-02-28 · Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia, Recurrent Severe Hypoglycaemia
What this study did
NCT01269034 · Albert Einstein College of Medicine
2010-12 – 2017-01-31 · Type 1 Diabetes
What this study did
NCT01269047 · Albert Einstein College of Medicine
2009-08 – 2016-12 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT07112339 · Novo Nordisk A/S
2025-08-15 – 2028-03-23 · Diabetes Mellitus, Type 2
What this study did
NCT05553093 · Nanjing First Hospital, Nanjing Medical University
2022-03-15 – 2027-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT03087032 · The First Affiliated Hospital of Xiamen University
2019-01-10 – 2025-02-10 · Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
What this study did
NCT06127433 · Sun Yat-sen University
2023-03-07 – 2024-12-30 · Insulin Pump,Continuous Glucose Monitoring Technology
What this study did
NCT03437330 · University Hospital Tuebingen
2021-10-27 – 2023-05-03 · Type2 Diabetes Mellitus
What this study did
NCT01107717 · The University of Texas Health Science Center at San Antonio
2009-01 – 2023-02-03 · Diabetes
What this study did
NCT05457933 · Medanta, The Medicity, India
2022-07-29 – 2023-01-14 · Type2diabetes, Coronary Artery Disease
What this study did
NCT05360537 · University of Palermo
2021-04-01 – 2022-04-20 · Diabetes Mellitus, Type 2
What this study did
NCT03336528 · Emory University
2018-01-02 – 2021-03-01 · Type 2 Diabetes
What this study did
NCT01919489 · Emory University
2014-03 – 2020-08-30 · Type 2 Diabetes
What this study did
NCT03687827 · Novo Nordisk A/S
2018-10-02 – 2019-12-27 · Diabetes Mellitus, Type 2
What this study did
NCT03819790 · LMC Diabetes & Endocrinology Ltd.
2018-10-02 – 2019-11-19 · Diabetes Mellitus, Type 2
What this study did
NCT02303730 · Fudan University
2015-03 – 2017-11 · Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
What this study did
NCT02004366 · Emory University
2014-01 – 2017-03 · Type 2 Diabetes
What this study did
NCT02453685 · Novo Nordisk A/S
2015-08-31 – 2016-09-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01845831 · Emory University
2013-08 – 2016-04 · Type 2 Diabetes
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT02250794 · Rush University Medical Center
2014-10 – 2015-05 · Type 2 Diabetes Mellitus
What this study did
NCT00766857 · Amsterdam UMC, location VUmc
2009-05 – 2012-12 · Type 2 Diabetes Mellitus, Congestive Heart Failure
What this study did
NCT01100125 · Seoul National University Bundang Hospital
2010-04 – 2012-11 · Diabetes
What this study did
NCT01175811 · Eli Lilly and Company
2011-02 – 2012-11 · Diabetes Mellitus, Type 2
What this study did
NCT01175824 · Eli Lilly and Company
2011-04 – 2012-11 · Diabetes Mellitus, Type 2
What this study did
NCT01417897 · ikfe-CRO GmbH
2011-09 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT00664534 · Eli Lilly and Company
2008-04 – 2010-11 · Diabetes Mellitus, Type 2
What this study did
NCT00353834 · Joslin Diabetes Center
2006-08 – 2010-09 · Type 2 Diabetes Mellitus
What this study did
NCT00909480 · Novo Nordisk A/S
2009-05 – 2010-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00699686 · University of Padova
2008-05 – 2010-03 · Type 2 Diabetes, Endothelial Dysfunction, Cardiovascular Disease
What this study did
NCT00279201 · Eli Lilly and Company
2005-12 – 2009-11 · Diabetes Mellitus, Type 2
What this study did
NCT00548808 · Eli Lilly and Company
2007-11 – 2009-08 · Type 2 Diabetes Mellitus
What this study did
NCT00377858 · Eli Lilly and Company
2006-08 – 2008-09 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT02061969 · Emory University
2014-04-25 – 2017-04-10 · Diabetes
What this study did
NCT01854723 · Providence Health & Services
2013-04 – 2015-12 · Diabetes
What this study did
Early phase / not applicable (8)
Type 1 Diabetes
NCT04965051 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-08 – 2023-12 · Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range
What this study did
NCT04101383 · Geropharm
2017-10-16 – 2018-02-16 · Clamp Study
What this study did
Type 2 Diabetes
NCT07652528 · Hallym University
2026-08 – 2028-12 · Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
What this study did
NCT03420040 · Xijing Hospital
2017-11-27 – 2018-04-01 · Type 2 Diabetes Mellitus
What this study did
NCT02887625 · Dr. Muhammad Abdulghani
2015-02 – 2017-05 · Type 2 Diabetes
What this study did
NCT01363609 · Amsterdam UMC, location VUmc
2011-10 – 2015-01 · Obesity, Type 2 Diabetes
What this study did
NCT00855439 · University of Michigan
2008-06 – 2014-05 · Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
What this study did
Other / comorbidity
NCT00574405 · Arkansas Children's Hospital Research Institute
2005-04 – 2011-03 · Diabetes Mellitus
What this study did
Appears in other studies (17)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Type 2 Diabetes
NCT04591626 · Eli Lilly and Company
2020-12-07 – 2022-04-28 · Type 2 Diabetes Mellitus
What this study did
NCT02738879 · Merck Sharp & Dohme LLC
2016-05-09 – 2018-01-30 · Type 2 Diabetes Mellitus
What this study did
NCT02033889 · Merck Sharp & Dohme LLC
2013-12-13 – 2017-08-03 · Type 2 Diabetes Mellitus
What this study did
NCT01698775 · Merck Sharp & Dohme LLC
2012-10-02 – 2016-01-19 · Type 2 Diabetes Mellitus
What this study did
NCT02152371 · Eli Lilly and Company
2014-05 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01462266 · Merck Sharp & Dohme LLC
2012-01-13 – 2013-06-07 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (3)
Type 1 Diabetes
NCT06111586 · Sanofi
2023-12-11 – 2030-10-29 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT00767000 · Merck Sharp & Dohme LLC
2008-10 – 2010-06 · Diabetes Mellitus, Type 2
What this study did
NCT00824616 · Merck Sharp & Dohme LLC
2009-01 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
Phase 4 (4)
Type 2 Diabetes
NCT02811484 · Weill Medical College of Cornell University
2016-06 – 2018-12 · Diabetes Mellitus, Type 2
What this study did
NCT02556918 · Emory University
2016-01 – 2018-11-06 · Hyperglycemia
What this study did
Other / comorbidity
NCT02741687 · Emory University
2016-06 – 2017-04 · Hyperglycemia
What this study did
NCT02443402 · Emory University
2016-01 – 2016-12 · Coronary Artery Disease
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Glargine (Lantus): this drugApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
IcoSema (Kyinsu)Phase 3PeptideInsulin receptor (basal), GLP-1 receptorPartial signal
NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001)
NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01)
Insulin Sudelidec (INS068)Phase 3PeptideInsulin receptor (basal)Partial signal
NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%)
NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%)
SHR-3167Phase 3PeptideInsulin receptor (basal)Partial signal
NCT06688123: Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.
GZR101Phase 2PeptideInsulin receptor (basal)Partial signal
NCT06199505: Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%).
IcovamenibPhase 2Small moleculeMeninPartial signal
NCT05731544: icovamenib showed a mean reduction in HbA1c of 0.36% (p=0.022). The strongest performing arm was Arm B (icovamenib dosed at 100mg QD for 12 weeks) with a mean HbA1c reduction of 0.5% (p=0.012).
UBT38006Phase 1PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 73 furthest-along competitors are listed; 77 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lantus (insulin glargine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Type 1 DiabetesRecruiting
Est. primary completion 2026-12 · NCT03463564 · CT.gov ↗
What to watch
2027 (3)
June 2027 (2)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-06-30 · NCT07173712 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06-30 · NCT07307235 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Pregestational Diabetes, PregnancyRecruiting
Est. primary completion 2027-12-01 · NCT07224893 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Phase 4Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, DiabetesEnrolling by invitation
Est. primary completion 2028-02-09 · NCT07117240 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 4Gestational Diabetes Mellitus, Pregnancy, High RiskRecruiting
Est. primary completion 2029-12 · NCT06445946 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 December 2024ApprovalEgyptian approval of EVA Pharma's insulin glargine injection
EG, EDA · Source ↗